"Here's what really breaks my heart about this technological gap: the moment when a newly diagnosed rare cancer patient sits down to find answers and...
Why Search Engines and LLMs Both Fail Rare Cancer and Rare Disease Patients
read more
Research & Innovation
2025 in Review: A Year of Strength and Growth
TargetCancer Foundation's (TCF) supporters and partners came together in meaningful ways in 2025, illustrating the strength and power of the rare cancer...
A Day That Left Me Hopeful for Rare Cancer Patients
This reflection was written by TCF volunteer Paul Oramasionwu On October 29, 2025, I spent the day at TargetCancer Foundation’s Think Tank on Advancing...
A Promise Fulfilled: 15 Years After Paul Poth’s Vision, a New Era in Cholangiocarcinoma Research Begins
A founding goal of TCF is realized as researchers identify potential drug targets and uncover novel disease subtypes through in-depth genetic and cellular...
Reshaping the Rare Cancer Research Landscape
We are excited to share the second video in our 15th Anniversary series, which focuses on TCF's research initiatives. Remarkable progress has been made across...
2023: An Impactful Year In Review
RESEARCH → TCF-001 TRACK Our fully remote, decentralized precision medicine clinical trial has enrolled 157 patients with 40 rare cancers from 41 states,...
A Reflection of Purpose After 13 years: Remembering Our Founder
Written by Kristen Palma, TargetCancer Foundation President Each year, as I sit down to write this note, I wonder what more I can say. It has been 13...
Honoring Our Past, Celebrating Our Progress: FDA Approves Tibsovo for Cholangiocarcinoma with IDH1 Mutation
Just a few days ago, we sent a remembrance of our founder, Paul Poth. It seems especially meaningful today to send along news of a different type- the very...
Promising New Cholangiocarcinoma Treatment Findings
An exciting paper was recently published in Cancer Discovery highlighting the promise of the recently FDA approved FGFR inhibitor drugs for an even broader...
Importance of Local Physicians at the TRACK Virtual Molecular Tumor Board
The rapid progress made over the last decade in bringing comprehensive genomic profiling to rare cancer patients has created the opportunity to significantly...
TRACK (Target Rare Cancer Knowledge) Virtual Molecular Tumor Board
The TRACK Study incorporates many features that make it unique and especially significant for rare cancer patients. One of these features is the Virtual...
Rare Cancer Research During COVID-19
By TCF research grant recipients Nabeel Bardeesy, PhD, of the Massachusetts General Hospital Cancer Center, and Adam Bass, MD of Dana-Farber Cancer...
An Insider’s Perspective
Dr. Monika Laszkowska, a gastroenterology fellow, next to the poster she presented at the 2019 TargetCancer Foundation Think Tank on Advancing...
2019 Cholangiocarcinoma Research Grant Announcement
TargetCancer Foundation is proud to announce a new two-year, $240,000 grant to the Bardeesy Lab at the Massachusetts General Hospital Cancer Center brings our...
Building the Tools of Cholangiocarcinoma Research – A Researcher’s Reflection.
In December 2019, TargetCancer Foundation announced $240,000 in new cholangiocarcinoma grant funding. The following post was written by Grant Recipient Nabeel...